<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533752</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01816</org_study_id>
    <nct_id>NCT02533752</nct_id>
  </id_info>
  <brief_title>Canadian WATCHMAN Registry</brief_title>
  <acronym>WATCHMAN</acronym>
  <official_title>Canadian WATCHMAN Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiology Research UBC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiology Research UBC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Canadian WATCHMAN Registry is a multicentre (8 Centres) Canadian prospective, non-randomized,
      registry to enrol 100 consecutive patients undergoing LAA closure with the WATCHAN device to
      study the safety and effectiveness of the WATCHMAN device
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia with current prevalence
      estimated at 1.5-2% of the general population. AF is a major cause of stroke, responsible for
      15% of all strokes and 30% of strokes in patients age &gt;80. Stroke is the leading cause of
      long-term disability and is the 4th leading cause of death in the US. Anticoagulation is the
      mainstay therapy for preventing strokes in AF with a 64% relative stroke reduction and 26%
      relative mortality benefit with warfarin therapy. Warfarin or newer anticoagulation
      treatments (NOAC) have been associated with increased risk of major bleeding and therefore a
      significant proportion (30-50%) of eligible patients do not receive therapy due to perceived
      risk of bleeding. The need for newer therapy is therefore required and percutaneous left
      atrial appendage closure (LAAC) devices have been investigated for patients with high risk of
      stroke and contra-indication to long term oral anticoagulation therapy. The WATCHMAN device
      is one of the leading LAA closure devices and with the most world-wide clinical experience.
      The investigators are running a multicentre (8 Centres) Canadian prospective, non-randomized,
      registry to enrol 100 consecutive patients undergoing LAA closure with the WATCHAN device to
      study the safety and effectiveness of the WATCHMAN device.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>From up to 24 Months from procedure</time_frame>
    <description>Composite: Cardiovascular death (or unexplained death), device embolization, stroke, systemic embolism, myocardial infarction, cardiac tamponade, major bleeding, and the need for cardiovascular surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term Events</measure>
    <time_frame>From hospital discharge to 24 Months</time_frame>
    <description>Composite: Overall mortality, cardiovascular mortality, ischemic and hemorrhagic stroke, systemic embolization, late device embolization (beyond hospitalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Technical Success</measure>
    <time_frame>Procedural (up to the end of procedure)</time_frame>
    <description>Procedure duration and complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>Procedural (up to hospital discharge)</time_frame>
    <description>Stroke (ischemic and hemorrhagic), air embolism, pericardial effusion (minor - not requiring intervention; serious - requiring percutaneous or surgical drainage), cardiac perforation, device embolization, major or life-threatening/disabling bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ability to switch to single antiplatelet therapy</measure>
    <time_frame>up to 3 Months from procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence and severity of residual leak</measure>
    <time_frame>up to 3 Months from procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of device thrombus</measure>
    <time_frame>up to 3 Months from procedure</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Main Group</arm_group_label>
    <description>This an observational registry - there is only one group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing WATCHMAN device Implantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years, and

          -  CHADS2 ≥1 and/or CHADS-VASc ≥2, and

          -  Prior major bleeding (intracranial, gastrointestinal bleeding, intraocular,
             respiratory, genitourinary, retroperitoneal, pericardial, anemia requiring
             transfusions, etc.), or contraindications to long-term OAC (HASBLED ≥3, high fall
             risk, cerebral aneurysm, blood dyscrasias, aortic dissection, etc.), or failure of OAC
             (stroke/TIA while on OAC)

        Exclusion Criteria:

          -  Presence of LAA thrombus

          -  Severe untreated mitral stenosis (no prior valve replacement)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Saw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Saw, MD</last_name>
    <phone>604 875 5547</phone>
    <email>jsaw@mail.ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Starovoytov, MD</last_name>
    <phone>604 875 5079</phone>
    <email>a.starovoytov@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sytarovoytov, MD</last_name>
      <phone>604 875 5079</phone>
      <email>a.starovoytov@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Saw, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4.</citation>
    <PMID>23831166</PMID>
  </reference>
  <reference>
    <citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987 Sep;147(9):1561-4.</citation>
    <PMID>3632164</PMID>
  </reference>
  <reference>
    <citation>Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e25-146. Epub 2007 Dec 17. Erratum in: Circulation. 2010 Jul 6;122(1):e10. Kissela, Bret [corrected to Kissela, Brett].</citation>
    <PMID>18086926</PMID>
  </reference>
  <reference>
    <citation>Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):e28-e292. doi: 10.1161/01.cir.0000441139.02102.80. Epub 2013 Dec 18.</citation>
    <PMID>24352519</PMID>
  </reference>
  <reference>
    <citation>Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998 Jun;31(7):1622-6.</citation>
    <PMID>9626843</PMID>
  </reference>
  <reference>
    <citation>Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008 Feb;99(2):295-304. doi: 10.1160/TH07-08-0508. Review.</citation>
    <PMID>18278178</PMID>
  </reference>
  <reference>
    <citation>Fagan SM, Chan KL. Transesophageal echocardiography risk factors for stroke in nonvalvular atrial fibrillation. Echocardiography. 2000 May;17(4):365-72. Review.</citation>
    <PMID>10979009</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiology Research UBC</investigator_affiliation>
    <investigator_full_name>Dr. Jacqueline Saw</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>Left Atrial Appendage Closure</keyword>
  <keyword>Watchman device</keyword>
  <keyword>LAA Closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

